Press Releases

Date Title and Summary Additional Formats
Toggle Summary Debiopharm International SA Enters the Field of Antibody-Drug Conjugates Through Acquisition of Phase II Asset from ImmunoGen
Transaction adds innovative clinical-stage program to expanding Debiopharm portfolio and broadens its clinical development expertise Divestiture aligns with ImmunoGen's focus on strategic growth initiatives and generates near-term value LAUSANNE, Switzerland & WALTHAM, Mass.
View HTML
Toggle Summary ImmunoGen Announces New Clinical Data with Mirvetuximab Soravtansine in Ovarian Cancer to be Presented at 2017 ASCO Annual Meeting
Pooled analyses of Phase 1 expansion cohorts demonstrate clinically meaningful activity in patient population being studied in FORWARD I registration trial Top-line data from FORWARD II indicate favorable safety and efficacy profile in multiple combinations Conference call scheduled for 8:00am ET
View HTML
Toggle Summary ImmunoGen Reports Recent Progress and First Quarter 2017 Operating Results
Phase 3 FORWARD I Trial of Mirvetuximab Soravtansine Activated in North America and Europe Data at AACR and SGO Annual Meetings Highlight Patient Selection Strategy for FORWARD I and Breadth of ADC Expertise Mirvetuximab Soravtansine Safety and Efficacy Data to be Presented at ASCO Annual Meeting
View HTML
Toggle Summary ImmunoGen Announces Results from Mirvetuximab Soravtansine Phase 1 First-in-Human Dose-Escalation Trial Published in Cancer
Data informed dosing in expansion cohorts and Phase 3 FORWARD I registration trial WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the results from a Phase 1
View HTML
Toggle Summary ImmunoGen Announces Conference Call to Discuss Its First Quarter 2017 Financial Results
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, May 5, 2017 to discuss its first quarter 2017
View HTML
Toggle Summary ImmunoGen Presents Phase 1 Biopsy Expansion Cohort Data at the Society of Gynecologic Oncology Annual Meeting
Data Confirm Use of Archival Tumor Tissue to Determine Patient Selection in FORWARD I WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that data from a mirvetuximab
View HTML
Toggle Summary ImmunoGen Announces Presentations at AACR Annual Meeting
Nine presentations featuring the Company's leadership in ADCs WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that nine abstracts highlighting the breadth of the
View HTML
Toggle Summary ImmunoGen Reports Recent Progress and Operating Results for Six-Month Period and Quarter Ended December 31, 2016
First Patient Enrolled in Phase 3 FORWARD I Trial of Mirvetuximab Soravtansine Continued Momentum in 2017 with Data Expected from Pipeline Programs Conference Call to be Held at 8:00am ET Today WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of
View HTML
Toggle Summary ImmunoGen Announces Webcasts of Presentations at Upcoming Investor Conferences
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast: Leerink
View HTML
Toggle Summary ImmunoGen Announces First Patient Dosed in FORWARD I Phase 3 Study of Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the first patient has been dosed in FORWARD I, the Company's Phase 3 clinical trial evaluating mirvetuximab
View HTML